Rezolute Inc Ordinary Shares RZLT 深 滬
已收盤 09-05 16:00:00 美东时间
8.00
+0.620
+8.40%
華盛通- 最 高8.055
- 今 開7.43
- 成交量 156.06万股
- 最 低 7.3401
- 昨 收 7.38
- 總市值 6.95亿
- 52周最高 8.055
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.215
- 委 比 -85.22%
- 總股本 8681.47万
- 歷史最高 21.11
- 量 比 1.73
- 振 幅 9.69%
- 歷史最低 0.72
- 每 手 1
- 風險率 1.01%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $14 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $14 price target.
09-03 19:12
Rezolute to Participate in Upcoming Investor Conferences
Rezolute, Inc. announced that its management will participate in three upcoming investor conferences in September 2025: the Cantor Global Healthcare Conference (September 3-5), the H.C. Wainwright 27th Annual Global Investment Conference (September 8-10), and the Morgan Stanley 23rd Annual Global Healthcare Conference (September 8-10). Management will engage in Fireside Chats and one-on-one investor meetings at these events. The Company focuses o...
08-27 11:30
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
Rezolute, Inc., a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), has appointed Sunil Karnawat as Chief Commercial Officer. With over 25 years of experience in global commercialization of biopharmaceuticals, including successful launches of ultra-rare disease therapies, Karnawat will lead the commercial strategy and global market readiness for ersodetug, the company's antibody therapy currently in ...
08-20 11:30
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
Rezolute, Inc. announced its participation in the BTIG Virtual Biotechnology Conference on July 29-30, 2025, where management will engage in one-on-one investor meetings. Rezolute focuses on treating hypoglycemia caused by hyperinsulinism and is advancing its antibody therapy, ersodetug, which has shown significant benefits in clinical trials.
07-22 11:30
Rezolute Files Prospectus To Resale Of 1.3M Shares Of Common Stock By Selling Stockholders
-SEC Filing
07-18 05:32
Rezolute to Present Late-Breaking Phase 3 Data on Rare Hypoglycemia Treatment at ENDO 2025
Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced that the abstract titled "Preliminary Patient
07-09 19:34
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
<p>Rezolute, Inc. announced that an abstract on its Phase 3 sunRIZE study of ersodetug for hypoglycemia caused by congenital hyperinsulinism (HI) has been selected for a late-breaking presentation at ENDO 2025. The study, which has completed enrollment, aims to assess the efficacy and safety of ersodetug in patients with HI. Ersodetug, a fully human IgG2 monoclonal antibody, targets the insulin receptor to reduce over-activation and improve hypog...
07-09 11:30
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
Rezolute announced the completion of enrollment in its Phase 3 sunRIZE study for ersodetug, with 62 participants, including approximately 15% from U.S. sites. The study evaluates the treatment of hypoglycemia in congenital hyperinsulinism (HI). Primary endpoints focus on weekly hypoglycemia events and time in hypoglycemia, with topline data expected in December 2025. Ersodetug, a monoclonal antibody targeting the insulin receptor, shows potential...
05-28 12:00
Rezolute Q3 EPS $(0.27) Misses $(0.23) Estimate
Rezolute (NASDAQ:RZLT) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 20.59 percent increase over losses of $(0.34) per share from the
05-14 04:27
Rezolute Closes $96.9 Million Underwritten Offering
Rezolute ( ($RZLT) ) just unveiled an announcement. On April 25, 2025, Rezolute...
04-29 05:29
